propionylpromazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5608 3568-24-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propionylpromazine
  • propiopromazine
  • propiopromazine hydrochloride
  • Molecular weight: 340.49
  • Formula: C20H24N2OS
  • CLOGP: 4.91
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 23.55
  • ALOGS: -4.80
  • ROTB: 6

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.691 Moderate 0.67
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.887 Moderate 0.67
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 27.353 10^-6 cm/s Moderate 0.67
dh-clint Dog hepatocyte intrinsic clearance 153.109 uL/min/10^6 cells Moderate 0.67
dppb Dog plasma protein binding (% unbound) 8.310 % Moderate 0.67
fcs-ppb Fetal calf serum protein binding (% unbound) 11.670 % Moderate 0.67
herg hERG pIC50 5.866 pIC50 Moderate 0.67
hh-clint Human hepatocyte intrinsic clearance 37.844 uL/min/10^6 cells Moderate 0.67
hlm-clint Human liver microsomal intrinsic clearance 41.976 uL/min/mg protein Moderate 0.67
hppb Human plasma protein binding (% unbound) 8.200 % Moderate 0.67
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.904 Moderate 0.67
mh-clint Mouse hepatocyte intrinsic clearance 246.037 Moderate 0.67
mppb Mouse plasma protein binding (% unbound) 9.440 Moderate 0.67
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.958 Moderate 0.67
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.67
pppb Pig plasma protein binding (% unbound) 23.520 % Moderate 0.67
rh-clint Rat hepatocyte intrinsic clearance 250.035 uL/min/10^6 cells Moderate 0.67
rh-fuinc Rat hepatocyte fraction unbound in incubation 39.510 % Moderate 0.67
rppb Rat plasma protein binding (% unbound) 9.480 % Moderate 0.67
solubility-dd Solubility at pH 7.4 in DMSO 731.139 uM Moderate 0.67

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Tranquilization Indication
Dogs Tranquilization Indication
Dogs Handling difficult, excited, and unruly dogs Indication
Dogs Car sickness Indication
Dogs Severe dermatitis Indication
Dogs Minor surgery and prior to routine examinations, laboratory procedures and diagnostic procedures Indication
Dogs Controlling excessive kennel barking Indication

🐶 Veterinary products

ProductApplicantIngredients
Tranvet Chewable Tablets (20 mg) Zoetis Inc. 1
Tranvet Injectable Solution Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
C026328 MESH_SUPPLEMENTAL_RECORD_UI
DB11540 DRUGBANK_ID
C0072200 UMLSCUI
7681-67-6 SECONDARY_CAS_RN
KEGG_DRUG
24352 PUBCHEM_CID
Y1BCT334I7 UNII
Y1BCT334I7 INXIGHT DRUGS

Pharmaceutical products:

None